肺癌分子靶向治疗分析

目的探讨和分析分子靶向治疗药物吉非替尼治疗肺癌的临床疗效,总结其临床价值。方法回顾性分析具有完整临床资料的2004年1月至2010年12月来我院就诊的肺癌患者40例,随机分为观察组和对照组两组,观察组给予紫杉醇进行治疗,对照组在此治疗方案的基础上给予分子靶向药物吉非替尼治疗,比较两组患者的临床治疗效果、患者生活质量、疾病进展情况以及不良反应情况。结果观察组和对照组经过4周时间的治疗后,肺癌患者的疾病得到一定程度的控制,病情得到缓解,但两组疗效具有显著性差异。结论采用分子靶向药物吉非替尼治疗肺癌具有疗效好,不良反应小等特点,值得临床进一步研究和探索。

Analysis on Molecular Targeted Therapy for Lung Cancer

Objective To investigate and analyze the clinic effect of molecular targeted gefitinib treatment on lung cancer,and summarize its clinical value.Methods A retrospective analysis was carried out on complete clinical data of 40 patients with lung cancer treated in our hospital from January 2004 to December 2010.The patients were randomly divided into two groups:control group and observation group.The control group were given paclitaxel treatment and the observation group were given paclitaxel plus molecular targeted drugs gefitinib.All patients were observed of clinical effect,quality of life,disease progression and adverse reactions.Results After 4 weeks of treatment,all the patients had a certain degree of control of the disease,and the condition had been alleviated.But there was significant difference in efficacy between the two groups.Conclusion The treatment with molecular targeted drugs gefitinib has good efficacy and fewer side effects in treating lung cancer.It is worthy of further study.